Cargando…

Should we measure clonal circulating plasma cells in light chain amyloidosis?

Detalles Bibliográficos
Autores principales:	Sidana, Surbhi, Kumar, Shaji K., Gonsalves, Wilson I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235020/ https://www.ncbi.nlm.nih.gov/pubmed/30479690 http://dx.doi.org/10.18632/oncotarget.26289

Ejemplares similares

Prognostic Significance of Circulating Plasma Cells by Multi-Parametric Flow Cytometry in Light Chain Amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2018)

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
por: Cuenca, Isabel, et al.
Publicado: (2020)

Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2020)

Flow cytometry‐based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis
por: Lisenko, Katharina, et al.
Publicado: (2016)

Importance of FISH genetics in light chain amyloidosis
por: Gertz, Morie A., et al.
Publicado: (2017)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Evaluation of laboratory diagnostic tests for light-chain clonality and bone marrow findings in AL amyloidosis
por: Lee, Taegeun, et al.
Publicado: (2023)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
por: Al Saleh, Abdullah S., et al.
Publicado: (2022)

Global epidemiology of amyloid light-chain amyloidosis
por: Kumar, Nishant, et al.
Publicado: (2022)

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2020)

Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
por: Gertz, Morie, et al.
Publicado: (2023)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
por: Warsame, Rahma, et al.
Publicado: (2020)

Respondent driven sampling—where we are and where should we be going?
por: White, Richard G, et al.
Publicado: (2012)

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
por: Bal, Susan, et al.
Publicado: (2023)

Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2020)

Localized Lymph Node Light Chain Amyloidosis
por: Dhakal, Binod, et al.
Publicado: (2015)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

Kappa light-chain amyloidosis of gastrointestinal tract
por: Hashimoto, Rintaro, et al.
Publicado: (2019)

Multiorgan involvement by amyloid light chain amyloidosis
por: Li, Guoliang, et al.
Publicado: (2019)

Localized Lymph Node Light Chain Amyloidosis
por: Yamamoto, Akira, et al.
Publicado: (2020)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Light chain amyloidosis presenting as retiform purpura
por: Soliman, Yssra S., et al.
Publicado: (2021)

Light chain cardiac amyloidosis in a nonagenarian
por: Takahashi, Koji, et al.
Publicado: (2022)

Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication
por: Baker, Kelty R.
Publicado: (2022)

COVID-19 and Light Chain Amyloidosis: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Should We Be Permissive with Hypercapnia?
por: Nassar, Boulos
Publicado: (2022)

What Should We Eat?
Publicado: (1909)

In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells
por: Gonsalves, Wilson I., et al.
Publicado: (2020)

Impact of renal impairment on light chain amyloidosis outcomes after autologous hematopoietic stem cell transplantation
por: Srour, Samer A., et al.
Publicado: (2020)

Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis
por: Zhang, Yang, et al.
Publicado: (2021)

In the light of COVID-19 oxygen crisis, why should we optimise our oxygen use?
por: Bonnet, Laure, et al.
Publicado: (2021)

Should we close small ventricular septal defects?
por: Viswanathan, Sangeetha, et al.
Publicado: (2017)

Apolipoprotein C-II Deposition Amyloidosis: A Potential Misdiagnosis as Light Chain Amyloidosis
por: Lohani, Sadichhya, et al.
Publicado: (2016)

Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina
por: Posadas-Martinez, Maria Lourdes, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_is516al7fg5pmv96b820b2va03